替吉奥联合吉西他滨治疗晚期胰腺癌的效果及对血清CA199水平、KPS评分的影响分析  

The effect of tegafur,gimeracil and oteracil porassium combined with gemcitabine in the treatment of patients with advanced pancreatic cancer and its influence on serum CA199 level and KPS score

作　　者：黄文波 HUANG Wen-bo(Panjin Central Hospital,Panjin 124010,China)

机构地区：[1]盘锦市中心医院,124010

出　　处：《中国现代药物应用》2022年第3期160-162,共3页Chinese Journal of Modern Drug Application

摘　　要：目的研究替吉奥联合吉西他滨治疗晚期胰腺癌的临床疗效及对血清糖类抗原199(CA199)水平、卡氏评分(KPS评分)的影响。方法74例晚期胰腺癌患者,随机分为对照组和观察组,各37例。对照组应用吉西他滨联合卡培他滨治疗,观察组应用替吉奥联合吉西他滨治疗。对比两组临床疗效、KPS评分及治疗前后血清CA199水平。结果观察组治疗客观缓解率(ORR)59.46%高于对照组的35.14%,差异具有统计学意义(P<0.05)。治疗后,观察组血清CA199水平(230.38±4.50)IU/ml低于对照组的(562.43±6.26)IU/ml,差异具有统计学意义(P<0.05)。治疗后,观察组KPS评分(80.47±3.25)分高于对照组的(76.35±2.93)分,差异具有统计学意义(P<0.05)。结论对晚期胰腺癌患者应用替吉奥联合吉西他滨治疗临床疗效较好,可有效降低肿瘤标志物水平,改善患者生存质量及预后。Objective To study the clinical efficacy of tegafur,gimeracil and oteracil porassium combined with gemcitabine in the treatment of patients with advanced pancreatic cancer and its influence on serum carbohydrate antigen(CA)199 level and KPS score.Methods A total of 74 patients with advanced pancreatic cancer were randomly divided into control group and observation group,with 37 cases in each group.The control group was treated with gemcitabine in combination with capecitabine,and the observation group was treated with tegafur,gimeracil and oteracil porassium in combination with gemcitabine.The clinical efficacy,Karnofsky performance status(KPS)score and serum CA199 levels before and after treatment were compared between the two groups.Results The objective response rate(ORR)59.46%of the observation group was higher than 35.14%of the control group,and the difference was statistically significant(P<0.05).After treatment,the serum CA199 level(230.38±4.50)IU/ml of the observation group was lower than(562.43±6.26)IU/ml of the control group,and the difference was statistically significant(P<0.05).After treatment,the KPS score(80.47±3.25)points of the observation group was higher than(76.35±2.93)points of the control group,and the difference was statistically significant(P<0.05).Conclusion Tegafur combined with gemcitabine has good clinical efficacy on patients with advanced pancreatic cancer,which can effectively reduce the level of tumor markers,and improve the quality of life and prognosis of patients.

关 键 词：晚期胰腺癌 吉西他滨 替吉奥 血清糖类抗原199 卡氏评分 

分 类 号：R735.9[医药卫生—肿瘤]